- Home
- IDN vs CTOR Comparison
IDN vs CTOR Comparison
Compare IDN & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- CTOR
- Stock Information
- Founded
- IDN 1994
- CTOR 2021
- Country
- IDN United States
- CTOR United States
- Employees
- IDN N/A
- CTOR N/A
- Industry
- IDN Computer Software: Prepackaged Software
- CTOR
- Sector
- IDN Technology
- CTOR
- Exchange
- IDN Nasdaq
- CTOR NYSE
- Market Cap
- IDN 59.5M
- CTOR 52.2M
- IPO Year
- IDN 1999
- CTOR N/A
- Fundamental
- Price
- IDN $5.09
- CTOR $0.90
- Analyst Decision
- IDN Strong Buy
- CTOR Buy
- Analyst Count
- IDN 3
- CTOR 2
- Target Price
- IDN $5.83
- CTOR $6.00
- AVG Volume (30 Days)
- IDN 526.6K
- CTOR 47.2K
- Earning Date
- IDN 05-13-2025
- CTOR 05-14-2025
- Dividend Yield
- IDN N/A
- CTOR N/A
- EPS Growth
- IDN N/A
- CTOR N/A
- EPS
- IDN N/A
- CTOR N/A
- Revenue
- IDN $20,211,000.00
- CTOR N/A
- Revenue This Year
- IDN $8.56
- CTOR N/A
- Revenue Next Year
- IDN $9.64
- CTOR N/A
- P/E Ratio
- IDN N/A
- CTOR N/A
- Revenue Growth
- IDN 4.55
- CTOR N/A
- 52 Week Low
- IDN $1.92
- CTOR $0.55
- 52 Week High
- IDN $5.46
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- IDN 76.01
- CTOR N/A
- Support Level
- IDN $3.67
- CTOR N/A
- Resistance Level
- IDN $5.46
- CTOR N/A
- Average True Range (ATR)
- IDN 0.51
- CTOR 0.00
- MACD
- IDN 0.18
- CTOR 0.00
- Stochastic Oscillator
- IDN 86.25
- CTOR 0.00
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.